免疫检查点抑制剂心脏毒性的临床热点与争议  

Clinical focused issues and controversies of cardiotoxicity of immune checkpoint inhibitors

作　　者：王阿曼[1] 方凤奇[1] 刘莹[2] 夏云龙[2] 刘基巍[1] WANG A-man;FANG Feng-qi;LIU Ying;XIA Yun-long;LIU Ji-wei(Department of Oncology,The First Affiliated Hospital of Dalian Medical University,Dalian 116011,China;Department of Cardiology,The First Affiliated Hospital of Dalian Medical University,Dalian 116011,China)

机构地区：[1]大连医科大学附属第一医院肿瘤科,辽宁省大连市116011 [2]大连医科大学附属第一医院心内科,辽宁省大连市116011

出　　处：《中国心血管病研究》2021年第2期180-185,共6页Chinese Journal of Cardiovascular Research

摘　　要：免疫检查点抑制剂(ICIs)使多种晚期恶性肿瘤的治疗模式开启了新变革。尽管免疫检查点抑制剂相关心脏毒性较为罕见,但致死性极高。以往研究中免疫检查点抑制剂心脏毒性的发生率被低估。本综述聚焦于目前免疫检查点抑制剂心脏毒性方面的研究进展,包括流行病学、评估、诊断、治疗和预后等。接受ICIs治疗者的最佳肿瘤心脏病管理模式仍面临诸多挑战。Immune checkpoint inhibitors(ICIs)have started revolutionizing the treatment of various advanced cancers.Although ICIs-related cardiotoxicity is rare,it has significant relevance due to the high mortality.Cardiotoxicity has largely been underestimated in previous studies of toxicity of ICIs.This review focuses on current knowledge about ICIs-related cardiotoxicity,including the incidence,assessment,diagnosis,treatment,prevention and prognosis.Future challenges are depicted for optimum cardio-oncology care of patients receiving ICIs therapy.

关 键 词：免疫检查点抑制剂 心脏毒性 诊断 治疗 

分 类 号：R54[医药卫生—心血管疾病]